News

OKYO Pharma Enters New Agreement with Tufts Medical Center

1 Mins read

The latest development from OKYO Pharma has sent the company’s share prices soaring by 19% to $2.23. In an exciting move, they have entered into a new agreement with Tufts Medical Center.

Clinical Trial for Neuropathic Corneal Pain

The agreement outlines plans for a 40-patient open-label clinical trial that will focus on evaluating the efficacy and safety of OK-101 in patients suffering from neuropathic corneal pain. This trial aims to provide valuable insights into the potential benefits of OK-101 for patients in a real-world clinical setting.

Milestones and Timelines

OKYO Pharma intends to file an Investigational New Drug application for neuropathic corneal pain in the fourth quarter of 2023. Once the application is allowed by the U.S. Food and Drug Administration, study enrollment will promptly commence. The trial is expected to be completed within six to nine months.

Budgetary Impact

Despite the significance of this trial, it is expected to have a minor budgetary impact. The total cost, including drug manufacture and formulation expenses for investigational use, is projected to be less than $1 million.

This collaboration between OKYO Pharma and Tufts Medical Center represents a significant milestone in advancing research and innovation in the field of neuropathic corneal pain treatment.

Related posts
News

Pi Coin Price Eyes Recovery Amid Oversold Conditions and Positive Market Signals - TokenPost

1 Mins read
Pi Coin has recently experienced notable volatility, with its price fluctuating within a narrow range amid weak growth. Despite limited upward momentum,…
News

xrp price prediction: XRP Price Forecast: Market decline continues as SOPR resets. Here's current market trends, retail demand, technical analysis and analysts insights todayheadline | Today Headline

1 Mins read
XRP Price Forecast shows Ripple trading near $2.26 on Friday after four consecutive days of decline. The cross-border payment token has faced…
News

Form 13G JADE BIOSCIENCES For: 16 October By Investing.com

1 Mins read
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment…

Leave a Reply

Your email address will not be published. Required fields are marked *